<DOC>
	<DOCNO>NCT01969669</DOCNO>
	<brief_summary>This open-label multicenter , study assess pharmacokinetic interaction ketoconazole ABT-199 12 subject relapsed refractory non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>A Study Assess Effect Ketoconazole Metabolism ABT-199</brief_title>
	<detailed_description>This Phase 1 study design ass body process study drug ABT-199 take alone combination ketoconazole ass safety ABT-199 combination ketoconazole . Subjects may enroll separate extension study continue receive ABT-199 completion study .</detailed_description>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Subject must relapse refractory nonHodgkin 's lymphoma . Subject must histologically document diagnosis nonHodgkin 's lymphoma define Bcell neoplasm World Health Organization ( WHO ) classification scheme except noted exclusion criterion . Subject Eastern Cooperative Oncology Group ( ECOG ) performance score 0 2 . Subject must adequate bone marrow ( independent growth factor support per local laboratory reference range ) , coagulation , renal hepatic function : Absolute Neutrophil Count ( ANC ) great equal 1000/µL ( without growth factor support unless neutropenia clearly due underlie disease ) ; Platelets great equal 75,000/mm3 ( unless thrombocytopenia clearly due diseaserelated immune thrombocytopenia underlie disease ; entry platelet count must independent transfusion within 14 day Screening ) ; Hemoglobin great equal 9.0 g/dL ( unless anemia clearly due underlie disease ; entry hemoglobin must independent transfusion within 14 day Screening ) ; If cytopenias present , evidence myelodysplastic syndrome hypoplastic bone marrow ; Subject must activate partial thromboplastin time ( aPTT ) prothrombin time ( PT ) exceed 1.5 × upper normal limit ( ULN ) ; Calculated creatinine clearance great equal 50 mL/min use 24hour urine collection creatinine clearance per CockcroftGault equation ; Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) less equal 3.0 × ULN institution 's normal range ; Bilirubin le equal 1.5 × ULN . Subjects Gilbert 's Syndrome may bilirubin great 1.5 × ULN per discussion AbbVie medical monitor . Subject diagnose PostTransplant Lymphoproliferative Disease ( PTLD ) , Burkitt 's lymphoma , Burkittlike lymphoma , lymphoblastic lymphoma/leukemia , chronic lymphocytic leukemia ( CLL ) , small lymphocytic lymphoma ( SLL ) , mantle cell lymphoma ( MCL ) . Subject receive combination antiretroviral therapy HIV ( due potential drugdrug interaction antiretroviral medication ABT199 , well anticipate ABT199 mechanism base lymphopenia may potentially increase risk opportunistic infection ) . Subject hypersensitivity ketoconazole . Subject cardiovascular disability status New York Heart Association Class great equal 2 . Class 2 define cardiac disease patient comfortable rest ordinary physical activity result fatigue , palpitation , dyspnea anginal pain . Subject significant history renal , neurologic , psychiatric , endocrinologic , metabolic , immunologic , cardiovascular , hepatic disease within past 6 month opinion investigator would adversely affect his/her participate study . Subject malabsorption syndrome condition preclude enteral route administration ( e.g. , prior surgical resection ) . Subject undergone allogeneic stem cell transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>non-Hodgkin 's lymphoma</keyword>
	<keyword>GDC-0199</keyword>
	<keyword>Safety</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>ABT-199</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Cancer</keyword>
</DOC>